Skip to main content

Advertisement

Table 3 Cardiovascular events of MSU crystal exposed and unexposed by subgroups

From: Is urate crystal precipitation a predictor of cardiovascular risk in hyperuricemic patients? A Danish cohort study

  MSU crystals No crystals Hazard ratio (95 % CI)
(events / person-years) (events / person-years) PS adjusted*
All 46 / 1026 34 / 1009 0.86 (0.52–1.43)
Age <60 14 / 698 4 / 577 1.31 (0.42–4.15)
Age 60–79 15 / 240 20 / 370 0.79 (0.36–1.76)
Age 80+ 17 / 88 10 / 62 0.79 (0.31–1.97)
Male 40 / 951 31 / 896 0.82 (0.47–1.41)
Female 6 / 75 3 / 113 1.87 (0.33–10.57)
No previous APTC 30 / 950 24 / 958 0.92 (0.48–1.74)
Only previous APTC 16 / 76 10 / 51 0.73 (0.28–1.94)
CKD 4 + 5 8 / 41 3 / 74 2.57 (0.57–11.55)
CKD 3 18 / 190 11 / 164 1.24 (0.54–2.86)
CKD 2 8 / 580 19 / 611 0.35 (0.13–0.89)
CKD 1 10 / 163 1 / 131 3.72 (0.44–31.23)
DM 11 / 103 9 / 102 0.79 (0.28–2.23)
No DM 35 / 923 25 / 907 0.93 (0.51–1.69)
Hypertension 22 / 245 10 / 214 1.69 (0.76–3.78)
Normotensive 24 / 781 24 / 795 0.64 (0.32–1.26)
  1. APTC AntiPlatelet Trialists’ Collaboration, CI confidence interval, CKD chronic kidney disease stages, DM diabetes mellitus, MSU monosodium urate, PS propensity score
  2. *All subgroups are PS adjusted. The no-crystal group was set as reference